Protecting hearing during chemotherapy with cisplatin
Hearing Protection in Cisplatin Chemotherapy
['FUNDING_R01'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-11012830
This study is looking at how a natural compound called honokiol might help protect your hearing while you receive cisplatin, a chemotherapy drug, so you can fight cancer without losing your hearing.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11012830 on ClinicalTrials.gov |
What this research studies
This research investigates how to prevent hearing loss caused by cisplatin, a common chemotherapy drug. It focuses on the use of honokiol, a natural compound that may protect hearing while still allowing cisplatin to effectively fight cancer. The study aims to understand how honokiol works at the cellular level to reduce damage from reactive oxygen species, which are harmful byproducts of chemotherapy. Patients may be involved in trials assessing the effectiveness of honokiol in preserving hearing during treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are scheduled to receive cisplatin as part of their treatment regimen.
Not a fit: Patients who are not receiving cisplatin or those with pre-existing severe hearing impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of hearing loss in cancer patients undergoing cisplatin chemotherapy.
How similar studies have performed: While the approach of using honokiol is promising, it is relatively novel and has not been widely tested in clinical settings for this specific purpose.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TAN, XIAODONG — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: TAN, XIAODONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.